Opinion|Videos|March 22, 2024
Recap: Bladder Cancer Treatment Algorithm
The Oncology Brothers recap the discussion on treatment practices for patients with bladder cancer.
Advertisement
Advertisement
Related to this article
ESMO 2026 posters showed durable EV-302 benefit in older and comorbid populations plus persistent early mortality in metastatic urothelial carcinoma.
In an exploratory KEYNOTE-B15 analysis, ctDNA clearance was higher with enfortumab vedotin plus pembrolizumab than with cisplatin and gemcitabine.
Perioperative pembrolizumab plus neoadjuvant cisplatin and gemcitabine did not significantly improve EFS vs placebo in cisplatin-eligible MIBC in KEYNOTE-866.
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
3
EU Approves T-DXd for HER2+ Early Breast Cancer With Residual Disease
4
Better Biomarkers Needed to Guide Neoadjuvant Chemoimmunotherapy in NSCLC
5